On Tuesday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Gevo, Inc. (NASDAQ:GEVO), ReneSola Ltd. (NYSE:SOL), Vericel Corporation (NASDAQ:VCEL), AMN Healthcare Services Inc. (NYSE:AHS)
Gevo, Inc. (NASDAQ:GEVO), with shares gained 5.33%, closed at $0.27.
ReneSola Ltd. (NYSE:SOL), with shares jumped 5.26%, settled at $1.60.
Vericel Corporation (NASDAQ:VCEL), with shares climbed 5.19%, and closed at $3.85.
AMN Healthcare Services Inc. (NYSE:AHS), surged 5.12%, and closed at $23.20, hitting new 52-week high of $23.30.
Latest NEWS regarding these Stocks are depicted underneath:
Gevo, Inc. (NASDAQ:GEVO)
Gevo, Inc. (GEVO), declared that Praj Industries Limited (“Praj”) has signed a memorandum of understanding (MOU) to become a Gevo licensee for producing renewable isobutanol at sugar-based ethanol plants.
Under the MOU, Praj will undertake to license up to 250 million gallons of isobutanol capacity for sugar-based ethanol plants over the next ten years. Gevo will market the isobutanol produced by Praj’s sub-licensees. Praj will also contribute process engineering and equipment services to expand isobutanol capacity at Gevo’s plant in Luverne, Minn, in addition to to improve yields and optimize energy consumption at the facility.
“We are very happy to be working with Praj and having them become an important licensee and partner. This new planned alliance demonstrates the flexibility of Gevo’s GIFT(R) technology to convert a wide range of sugar sources into isobutanol. It also continues to validate the interest in licensing our intellectual property portfolio as we look to transition our business to focus more on a licensing model,” said Dr. Patrick Gruber, Gevo’s Chief Executive Officer.
Gevo, Inc., a renewable chemicals and biofuels corporation, focuses primarily on the production and sale of isobutanol and related products from renewable feedstocks. Isobutanol is a four-carbon alcohol, which is used as a specialty chemical in the production of solvents, paints, and coatings or as a value-added gasoline blendstock.
ReneSola Ltd. (NYSE:SOL)
Kandi Technologies Group, Inc. (KNDI), declared that Kandi has designated Mr. Cheng (Henry) Wang as the Corporation’s new Chief Financial Officer, effective May 1, 2015.
Mr. Wang has over 20 years of international financial administration experience. Before joining Kandi, Henry served as Chief Financial Officer for Shanghai Always Marketing Service Co., LTD., one of the largest field marketing service agencies in China, leading its procurement and finance departments since May 2014. Preceding to that, Mr. Wang worked for ReneSola Ltd. (SOL), an international leading brand and technology provider of green energy products, initially as the Vice President of Finance, ascending to Chief Financial Officer in July 2011. Mr. Wang holds both certifications as Certified Public Accountants (“CPA”) in China and Certified Internal Auditor (“CIA”), and earned a Master’s degree in Law from Renmin University of China and a Master’s of Business Administration from the Open University of Hong Kong.
Kandi Technologies Group, Inc. (KNDI), headquartered in Jinhua, Zhejiang Province, is engaged in the research and development, manufacturing and sales of various vehicle products.
ReneSola Ltd, through its auxiliaries, manufactures and sells various solar power products. It operates through two segments, Wafer, and Cell and Module. The corporation offers virgin polysilicon; mono crystalline and multi crystalline solar wafers; and photovoltaic cells.
Vericel Corporation (NASDAQ:VCEL)
Vericel Corporation (VCEL), stated financial results for the fourth quarter and year ended December 31, 2014. Total proceeds for the fourth quarter and year-end 2014 were generated primarily from net sales of Carticel(R) (autologous cultured chondrocytes) implants and surgical kits and Epicel(R) (cultured epidermal autografts), which were attaind on May 30, 2014 as part of the attainment of Sanofi’s cell therapy and regenerative medicine business.
Vericel stated a net loss for the quarter and year ended December 31, 2014 of $2.4 million, or $0.17 per share, and $19.9 million, or $2.23 per share, respectively, contrast to a net loss of $2.9 million, or $0.97 per share, and $15.6 million, or $6.95 per share, for the same periods in 2013.
Total net proceeds for the quarter ended December 31, 2014 were about $14.7 million and comprised of about $11.4 million of net sales of Carticel implants and surgical kits and about $3.3 million of net sales of Epicel. Total Carticel and Epicel net product proceeds in the fourth quarter raised about 13% over the same period in 2013 preceding to the attainment.
Total net proceeds for the year ended December 31, 2014, which comprise seven months of Carticel and Epicel sales, were about $28.8 million and comprised of about $22.3 million of net sales of Carticel implants and surgical kits and about $6.0 million of net sales of Epicel. Total Carticel and Epicel net product proceeds for the June through December period raised about 9% over the same period in 2013 preceding to the attainment.
Gross profit for the quarter ended December 31, 2014 was $8.0 million, or 54% of net product sales. Gross profit for the year ended December 31, 2014 was $11.5 million, or 40% of net product sales. Cost of product sales for the full year comprises $2.5 million in restructuring costs. The improved margins in the fourth quarter resulted from an improvement in the Carticel implant-to-biopsy and higher fourth quarter volumes.
Other revenue for the quarter and year ended December 31, 2014 was less than $0.1 million and $3.6 million, respectively, contrast to $2.0 million and $5.3 million for the same periods a year ago. The decrease in other revenue for the full year is due primarily to a decrease in the fair value of warrants in 2013 contrast to 2014 offset by the $3.5 million bargain purchase gain in 2014. The change in other revenue for the quarter is primarily due to an raise in other revenue attributable to a decrease in the fair value of warrants in the fourth quarter of 2013 contrast to the same period in 2014.
Vericel Corporation (formerly Aastrom Biosciences, Inc.), a clinical-stage biotechnology corporation, focuses on the development of cell therapies for use in the treatment of severe chronic ischemic cardiovascular diseases.
AMN Healthcare Services Inc. (NYSE:AHS)
On Tuesday, UBS Research Firm has upgraded AMN Healthcare Services Inc. (AHS)’s stock from “Neutral” to “Buy.”
Formerly the company presented at the Sidoti 19th Annual Emerging Growth Institutional Investor Forum on Tuesday, March 17, 2015, at the Grand Hyatt Hotel in New York, New York.
AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Healthcare Staffing, Locum Tenens Staffing, and Physician Permanent Placement Services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
